Monopar Therapeutics Inc. Made Headway

Mon, Nov 07, 2022 at 07:51 PM
Monopar Therapeutics Inc. Made Headway

Monopar Therapeutics Inc. (MNPR:NASDAQ) soared at $3.95, representing a gain of 32.6%. On Mon, Nov 07, 2022, MNPR:NASDAQ hit a New 2-Week High of $3.95. The stock got featured on our News Catalysts scanner on Wed, Oct 19, 2022 at 11:17 AM in the 'MISCELLANEOUS' category. From Tue, Oct 25, 2022, the stock recorded 77.78% Up Days and 60.00% Green Days

About Monopar Therapeutics Inc. (MNPR:NASDAQ)

Monopar Therapeutics Inc is the United States-based clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. Its pipeline products comprise of Validive, Camsirubicin, and MNPR-101.

Get 50% Off Premium Subscription
$19.99 USD
Limited-Time Discount
$9.99 USD
Signup 7 Days Trial. No Credit Card Required!
Ever wanted to explore stocks that have recently spiked... stocks moving sideways... gaps... or other trends? You're in the right place! Check StockTreats features.